Swedish national pension buffer funds AP1 and AP4 intend on investing in Cantargia AB, a domestic biotechnology firm that is seeking to develop an antibody-based treatment for a number of forms of cancer. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]